The government has already struck off 226,000 companies from the register for not filing statutory returns
Once the patients are identified, the government will decide on the quantum of compensation in each case and then approach J&J for claim settlement.
Rough estimates show that at a rate of Rs 1 crore per hospital bed, the investment in India alone would be around Rs 2,000 crore
These courts will be set up in Mumbai, Delhi, Chennai, Kolkata, and Hyderabad
Some of the popular brands that would be impacted include Phensedyl (Abbott), Tixylix (Abbott), Gluconorm PG (Lupin), Ascoril D (Glenmark), Solvin Cold (Ipca), D Cold Total (Paras Pharma).
Apart from shell companies, 'vanishing' companies are also on the ministry's radar. As many as 400 companies are not traceable, despite being listed on the bourses.
In its investor presentation, IHH said it wanted to develop Fortis into a market leader.
911 have been traced by the Securities and Exchange Board of India (Sebi), while the rest of the 402 are not traceable on the bourses
Experts believe the move will have little impact given limited production of generic drugs and authority of doctors in prescribing medicines.
When shares in the electronic form are available with the depositories, it acts as primary evidence for those who hold the shares.
Of the Rs 4,405 crore unpaid debt of 12 companies, more than half was locked in just one Mumbai-based real estate company, Kohinoor CTNL Infrastructure.
In May, price growth for drugs was in negative territory at (-)1 per cent
While farmers in Gujarat are rejecting the compensation package, farmers in Maharashtra say they do not wish to part with their land for a project that largely benefits Gujarat.
Their offer values Fortis at over Rs 9,000 crore, or around Rs 172 per share.
Thousands of unlisted companies registered with RoCs will soon go under watch on lines similar to the oversight by the Securities and Exchange Board of India of listed companies.
After taking action against 226,000 shell companies last year, the ministry of corporate affairs has now zeroed in on a fresh batch of suspected shell companies.
Bhavdeep Singh, the CEO of Fortis Healthcare said that they haven't been able to focus on the business due to an internal issue, especially with regard to the promoters
By April, operational guidelines for the scheme will be finalised and shared with states
While the basic premise and spirit of the Code will remain the same, the commas and the full-stops in the draft report being prepared by a high-level committee will make interpretation of the law simpler
The rules are being framed to maintain absolute transparency and fair play in investigations.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances